Antiangiogenesis

Benefits of antivascular agents contingent on vessel maturity

Published in Cancer Weekly, February 11th, 2003

by Sonia Nichols, senior medical writer - Tumor neovascularization takes place similar to that of physiological neovascularization. Tracking vessel maturity is key to ensuring that tumors respond as desired to antivascular agents, according to a U.S. study.

Because the impact of antiangiogenesis agents on the vessels they target has not been thoroughly explored, researchers at the University of Pennsylvania in Philadelphia undertook a study to better understand how antivascular agents affect vessels during their development.

"Hypothesizing that the response of vessels to therapy is influenced by their stage of maturation, we studied vascular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-02-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry